Wyeth (NYSE: WYE) and Elan Corp. (NYSE: ELN) reported mixed results for its mid-stage drug tests to treat Alzheimer's disease and planned to proceed with late-stage studies. Shares of Wyeth climbed $2.08 to close at $45.16 while Elan stock surged $2.89 to close at $30.00.
